figitumumab + docetaxel

rejuvenator **Figitumumab + docetaxel** is a combination therapy comprising figitumumab, a fully human monoclonal antibody that targets the insulin-like growth factor type 1 receptor (IGF-1R), and docetaxel, a taxane-class chemotherapeutic agent. - **Figitumumab** acts by binding to IGF-1R, blocking the interaction of IGF-1 and IGF-2 and inhibiting downstream signaling involved in tumor cell proliferation and survival. It promotes prolonged receptor internalization and degradation. - **Docetaxel** disrupts microtubule dynamics, inhibiting cell division and leading to apoptosis in proliferating cancer cells. - The combination was studied in patients with advanced solid tumors, primarily metastatic castration-resistant prostate cancer, as well as other cancers. - Clinical studies indicate additive or synergistic antitumor activity, but increased toxicity has been noted, particularly hyperglycemia, diarrhea, and fatigue, compared to docetaxel alone. - The combination is administered intravenously. - Developed and investigated by Pfizer for figitumumab, with docetaxel manufactured by Sanofi and other companies[1][2][3].

Other names

figitumumab + docetaxel